RFK Jr. is playing with babies' lives
He had a long history of indulging conspiracy theories, particularly when it came to vaccines. Already, his attempt to re-assess immunization schedules in the U.S. has outraged pediatricians. But his latest broadside against science, a decision to withdraw U.S. funding from the global vaccine alliance GAVI, may kill far more children than anything he has so far tried at home.
The Global Alliance for Vaccines and Immunization, designed in cooperation between the U.S. and U.K. governments, as well as philanthropic organizations — particularly Bill and Melinda Gates' foundation — was set up in 2000. Its mandate has been to increase access to vaccines for children whose families cannot afford them, primarily in the Global South. GAVI could have done more, especially during the COVID-19 pandemic, but even so it is fair to describe it as one of the few great success stories for international collaboration in the past few decades.
It's worth taking a moment to examine exactly how effective it has been at saving lives through its sustained focus on routine childhood vaccinations. One study published in the British Medical Journal calculated that its support for immunization programs across the world had reduced infant mortality rates by over 9% and under-fives by 12%.
During the pandemic, GAVI helped set up and administer the COVAX system for vaccine distribution to poorer countries. This took a while to get started, but eventually delivered 2 billion doses of various COVID-19 shots, saving hundreds of thousands, possibly millions, of lives. Initially, the Global South saw the developed world hog far more doses than they needed — Canada, a country of 40 million, had reserved 154 million doses by December of 2020 — while most other countries had simply no way to access any shots at all. GAVI, through COVAX, played a central role in addressing this shocking disparity.
Kennedy's decision to end support to one of America's few remaining positive interventions in the Global South is both immoral and dangerous. It will cause resentment about inequities in worldwide health care access to spread and further damage U.S. standing abroad when compared to countries like China.
Kennedy's deference to conspiracy theories and nativism will cost children their lives. It may even wind up being worse than the decision to stop funding USAID programs, which has already led to chaos in the some of the poorest parts of the world. (A study published in The Lancet just recently predicted those cuts could result in more than 14 million extra deaths globally by 2030.)
But it will hurt the U.S. as well. Not just because Americans cannot insulate themselves completely from an unhealthy world — the pandemic taught us that. But also because GAVI was designed around the principles of the market, and respect for intellectual property rights, institutions that serve U.S. companies and consumers most of all.
Critics argue that it is far too respectful of property rights and the profit motive. The charity Médecins Sans Frontieres, for example, has complained that GAVI pays too much to the rights-holders and developers of vaccines, instead of to generics manufacturers, and that means that it costs more to immunize each child than it needs to. (Still, MSF acknowledges that half of the vaccinations it delivers every year are bought with GAVI money, and responded to Kennedy's withdrawal of funding by saying that now, "countless children will die from vaccine-preventable diseases.')
The fact is that if GAVI goes, then so will many countries' incentives to respect intellectual property rights in the health care sector. The last thing that U.S. companies — not just in pharmaceuticals, but across the board — need is for the future centers of economic growth in the Global South to take a pick-and-choose approach to paying rights holders.
And all of us will be hurt if new and innovative medicines aren't developed because the global norms around rights and payments change. If Kennedy is allowed to follow his anti-science instincts then the U.S. will be left unhealthier, less respected and poorer — and a million children in the rest of the world will never live to see adulthood.
Mihir Sharma is a Bloomberg Opinion columnist. A senior fellow at the Observer Research Foundation in New Delhi, he is author of "Restart: The Last Chance for the Indian Economy.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
7 days ago
- Japan Times
U.S. health department hands over Medicaid personal data to ICE
The U.S. health department is giving Immigration and Customs Enforcement (ICE) officials access to the personal data of 79 million Medicaid enrollees to help them track down immigrants who may not be living legally in the country, it said on Thursday. Giving ICE access to the personal data of Medicaid enrollees marks an escalation in U.S. President Donald Trump's hard-line immigration policies. It may also raise privacy concerns under the Health Insurance Portability and Accountability Act, known as HIPAA. A Department of Health and Human Services spokesperson said sharing data between the Centers for Medicare and Medicaid Services (CMS) and the Department of Homeland Security (DHS), which oversees ICE, fell within the department's legal authority. "With respect to the recent data sharing between CMS and DHS, HHS acted entirely within its legal authority — and in full compliance with all applicable laws — to ensure that Medicaid benefits are reserved for individuals who are lawfully entitled to receive them," the spokesperson said. A spokesperson for the Department of Homeland Security said the department was exploring an initiative with CMS to ensure people living in the country illegally do not receive Medicaid benefits. The agreement was first reported earlier on Thursday by the Associated Press, which said it was signed on Monday. The Medicaid health program for low income people is jointly funded by the federal government and states. Immigrants who are in the U.S. illegally are not eligible for Medicaid under federal law, but 14 states and the District of Columbia provide coverage for eligible children regardless of immigration status, and seven states and the district do so for adults. "CMS is aggressively cracking down on states that may be misusing federal Medicaid funds to subsidize care for illegal immigrants. This oversight effort — supported by lawful interagency data sharing with DHS — is focused on identifying waste, fraud, and systemic abuse," the HHS spokesperson said. The spokesperson did not address questions from Reuters on the type of data being shared or on how HHS would ensure HIPAA protections are upheld. The AP, citing a copy of the data sharing agreement, said the data included home addresses and ethnicities. The agreement is the latest in a series of moves by the health department in support of the Trump administration's immigration crackdown and comes a week after it widened its interpretation of a law banning most immigrants from receiving federal public benefits.
NHK
16-07-2025
- NHK
Japan govt. disposes of expired oral coronavirus drugs for 2.5 million people
Japan's health ministry says oral COVID-19 drugs for about 2.5 million people were disposed of after passing their expiry dates. Based on the special anti-virus law, the government purchased three types of oral coronavirus drugs to treat about 5.6 million people. It supplied them for free to medical institutions and pharmacies through May 2023, when the government downgraded COVID-19 to the same level as the seasonal influenza. The health ministry says PaxlovidPACK for about 1.75 million people and Lagevrio for about 780,000 people were disposed of by the end of February. The ministry also says that Xocova for about 1.77 million people is expected to be discarded by the end of July next year. The ministry says it has considered ways to utilize the drugs. However, officials decided to dispose of them after considering how their supply for free could impact the drug market. The ministry explains that the purchase was made to ensure the provision of coronavirus medication for people needing them, as their initial supply was limited.
Japan Times
14-07-2025
- Japan Times
China biotech's stunning advance is changing the world's drug pipeline
The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China — for cancer, weight-loss and more — entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the U.S.'s count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's center of gravity. With U.S. President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances — the scale of which is slowly coming into view — risk becoming another realm of superpower rivalry like artificial intelligence and electric vehicles. "The scale itself is not something we've seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. "The products are here, they're attractive and they're fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6% of the total, behind Japan and the U.K. The reforms helped streamline reviews, enforced data quality standards and improved transparency. The government's "Made in China 2025" plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. "Not only is it now almost at parity with the U.S. but it has that growth trajectory,' said Daniel Chancellor, vice president of thought leadership at Norstella. "It wouldn't be sensationalist to suggest that China will overtake the U.S. in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs like Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech, it is now marketed by Johnson & Johnson — having won a few expedited review designations along the way — and considered superior to a competing U.S.-originated therapy. Still, the absolute number of China-originated drugs winning these designations trails their U.S. counterparts by a large margin. Risk aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before — an endeavor that comes with a high risk of failure and is still led by the U.S., Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso, which came out more effective than Merck & Co.'s Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics, which in 2022 paid $500 million upfront for the development and marketing rights in the U.S. and other regions. Other multinational players like Merck, AstraZeneca and Roche Holding have also scooped up Chinese assets. In May, Pfizer set a new record as it announced a $1.2 billion upfront deal with 3SBio for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signaling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, which have a constant need to add new products to the mix, can "cast their net wider than ever before,' Norstella's Chancellor said. A key advantage that has fueled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Technicians work inside a production laboratory for CAR-T cell therapies at an IASO Biotechnology facility in Nanjing on June 9. | Bloomberg Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralized hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster — for early trials for cancer and obesity drugs, they can complete patient enrollment in half the time compared to the U.S. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. "They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. U.S. regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins U.S. and EU approvals — the gold standard for high-quality treatments — and becomes widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs, and old-guard Chinese pharmaceutical companies like Jiangsu Hengrui Pharmaceuticals, which used to be one of the country's biggest generic drugmakers. The company poured billions of dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020-2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. "As we move forward, the fact that there's high quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. "It'll just be an accepted part of the norm.' At a time when China and the U.S. are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the U.S. risks losing its leadership position in yet another industry critical to national security. "Biotech is one of the forefronts of the U.S.-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponized in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the U.S. government to stymie China's biotech growth — through restrictions such as export controls on scientific equipment and barriers to investment — and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F. Kennedy, the U.S. Secretary of Health and Human Services, recently pledged to "Make American Biotech Accelerate.' Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers like Akeso have set their sights on bringing their therapies to developed Western markets. "The pharma industry is the best industry in the world,' Akeso CEO Michelle Xia said in an April interview. "At the end of the day, what we do benefits patients in China, in the U.S. and all around the world.'
